Advertisement


Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

2024 ASCO Annual Meeting

Advertisement

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the dynamic is a randomized trial looking at the utility of using CtDNA to guide adjuvant treatment in stage two colon cancer. The rationale behind the study is the fact that the role of adjuvant chemotherapy remains debatable in stage two colon cancer where surgery cured the majority of patients and to date, there has been very little evidence of survival benefit with the use of adjuvant chemotherapy. Our prior work have shown that detection of CtDNA after surgery is highly prognostic, where almost all patient recurred if left untreated. So this is a non-inferiority study that randomized patient to two-thirds receiving CtDNA guided management and one-third of standard management. So in the CtDNA guided group, patient with a positive result after surgery receive adjuvant chemotherapy and patient with a negative result were just observed. So the key findings from the study is that we have reduced the use of adjuvant chemotherapy by using CtDNA compared to standard management from 28% down to 15%, but we did not compromise recurrence-free survival. The updated results from dynamics showed that even at 5 years, the recurrence-free survival was 88.3% in the CtDNA guided group, and 87.2% with that of management of not using the blood test and the lower bound of the 95 confidence interval remains above the non-inferiority margin, again, confirming the non-inferiority of this approach. The overall survival between the two arms are similarly very favorable, ranging around 93%, which is very impressive. Intriguingly, we found that more than half the patient, substantial proportion of the death events in the study were not due to colorectal cancer recurrence resulting in a disease-specific survival, exceeding 97% across both arms. Another interesting finding is that we collected serial bloods on patient who have CtDNA positive and receive adjuvant chemotherapy. We found a very high clearance rate of 87.5% of CtDNA clearance following adjuvant chemotherapy, and patients who cleared a CtDNA had exceedingly good recurrence-free survival compared to patient who did not clear their CtDNA. So we also found that in untreated CtDNA negative T4 tumor, their overall survival is excellent at 19.6%. The implication for clinical practice is that using CtDNA to guide therapy compared to not having the blood test in stage two colon cancer can reduce the use of adjuvant chemotherapy without compromising patient's outcome and that CtDNA clearance rate is very high, supporting the benefit of adjuvant chemotherapy in this very high-risk population.

Related Videos

Breast Cancer

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).

Multiple Myeloma

Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients

Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (Abstract 7502).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Advertisement

Advertisement




Advertisement